MC2 Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsMC2 Therapeutics

MC2 Therapeutics

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Wynzora	Betamethasone, Calcipotriene	2020-07-20	2027-2039	Psoriasis , Atopic dermatitis , Pruritus ani , Inflammation , Facial dermatoses , Seborrheic dermatitis , Foot dermatoses , Hand dermatoses , Scalp dermatoses , Leg dermatoses , Mycoses , Oral candidiasis , Vulvovaginal candidiasis , Tinea pedis , Cutaneous candidiasis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

healthy volunteers/patients

alopecia areata

,

,

localized scleroderma

,

,

squamous cell neoplasms

,

vasoconstriction

,

photoallergic dermatitis

,

phototoxic dermatitis

,

healthy volunteers/patients

,

systemic scleroderma

,

,

breast neoplasms

,

connective tissue diseases

,

,

,

organ transplantation

,

drug-related side effects and adverse reactions

,

mesenchymal stem cell transplantation

,

,

,

,

,

radiodermatitis

,

squamous cell carcinoma

,

follicular lymphoma

,

,

,

,

,

basal cell carcinoma

,

squamous intraepithelial lesions

,

,

actinic keratosis

,

,

skin and connective tissue diseases

,

,

atopic dermatitis

,

coronary artery disease

,

erythema multiforme

,

,

papulosquamous skin diseases

,

contact dermatitis

,

graft vs host disease

,

,

bites and stings

,

topical administration

,

allergic contact dermatitis

,

insulin resistance

,

blood coagulation disorders

,

,

blood platelet disorders

,

hemostatic disorders

,

coagulation protein disorders

,

oral lichen planus

,

,

Betamethasone dipropionate

healthy volunteers/patients

Bos taurus adrenal cortex corticosteroids

,

precursor cell lymphoblastic leukemia-lymphoma

,

,

respiratory insufficiency

,

,

bronchiolitis obliterans syndrome

,

giant cell arteritis

,

polymyalgia rheumatica

,

lupus nephritis

,

multiple myeloma

,

breast neoplasms

,

,

,

animal mammary neoplasms

,

ornithine carbamoyltransferase deficiency disease

,

,

,

,

,

pulmonary sarcoidosis

,

,

,

b-cell chronic lymphocytic leukemia

,

hypersensitivity

,

,

healthy volunteers/patients

,

,

,

systemic lupus erythematosus

,

prostatic neoplasms

,

urogenital neoplasms

,

male genital neoplasms

,

hematopoietic stem cell transplantation

,

,

granulomatosis with polyangiitis

,

anti-neutrophil cytoplasmic antibody-associated vasculitis

,

microscopic polyangiitis

,

obstructive lung diseases

,

,

graft rejection

,

psychology rejection

,

thrombocytopenic purpura idiopathic

,

follicular lymphoma

,

,

thrombocytopenia

,

,

nephrotic syndrome

,

,

,

,

,

kidney transplantation

,

,

chronic obstructive pulmonary disease

,

graft vs host disease

,

liver transplantation

,

atopic dermatitis

,

,

,

renal insufficiency

,

chronic kidney failure

,

kidney diseases

,

,

cytomegalovirus infections

,

communicable diseases

,

heart transplantation

,

multiple sclerosis

,

,

chronic renal insufficiency

,

,

renal replacement therapy

,

drug-related side effects and adverse reactions

,

,

relapsing-remitting multiple sclerosis

,

cystic fibrosis

,

allergic bronchopulmonary aspergillosis

,

transplantation

,

end stage liver disease

,

,

disease progression

,

vasoconstriction

,

photoallergic dermatitis

,

phototoxic dermatitis

,

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use